Patrizia Cavazzoni will rejoin Pfizer Inc. as chief medical officer and executive vice president.
FDA has withdrawn a proposed rule that called for standardized testing for detecting and identifying asbestos in talc-containing cosmetic products.
Former CDER Director Patrizia Cavazzoni named Pfizer chief medical officer, executive vice president
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
Scott Gottlieb, a former FDA commissioner, said a recent decision by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices’ to change its recommendation for when children should receive the hepatitis B vaccine is another sign of the ACIP’s diminished credibility as a scientific authority.
Curebound has announced eight grants for a total of $2 million in funding. The funding is made available through two new Curebound programs: Catalyst Grants, which support projects within early-stage life science companies that are seeking to take innovative discoveries to commercially approved products, and Equity Grants, which focus on overcoming disparities in cancer research and treatment in underserved populations.
After three weeks of brutal combat, Richard Pazdur decided that he has had enough.
Vinay Prasad, FDA’s chief medical and scientific officer and director of the agency’s Center for Biologics Evaluation and Research, has instructed his staff to check with him before continuing to work on ongoing submissions to journals or beginning new contract-funded projects to “ensure that we are not engaging in sunk cost fallacy, not publishing obviously erroneous work, and not being distracted from our core mission.”
FDA issued a draft guidance on Dec. 2, outlining specific product types for which the FDA believes six-month non-human primate toxicity testing can be eliminated or reduced.
